Urine Protein Panels Identify Prostate Cancer and Differentiate between Tumors
By LabMedica International staff writers Posted on 12 Jul 2016 |
Image: A micrograph of a prostate adenocarcinoma, acinar type, the most common type of prostate cancer. Needle biopsy, H&E stain (Photo courtesy of Nephron).
A noninvasive diagnostic test for prostate cancer is based on protein signatures that can differentiate patients from healthy individuals and those with aggressive tumors from those with less dangerous growths.
Investigators at the Ontario Institute for Cancer Research (Toronto, Canada) and their colleagues at the University Health Network (Toronto, Canada) and the Eastern Virginia Medical School (Norfolk, VA, USA) used advanced proteomics techniques to generate expression information for 624 proteins obtained in urine samples. Computational analyses reduced this number by identifying significantly differentially expressed proteins and finally characterized a set of six protein biomarkers for diagnosis and a set of seven protein biomarkers for prognosis of prostate cancer.
"The amazing thing about these signatures is that their rate of accuracy is as good or better than the invasive tests that are used today, with far fewer drawbacks," said contributing author Dr. Paul Boutros, a principal investigator at the Ontario Institute for Cancer Research. "They can replace invasive, expensive, uncomfortable tests with something much easier and simpler. This type of cheap, non-invasive testing could allow patients to be screened much more frequently, allowing for more accurate monitoring of patients' non-aggressive cancer over time, sparing patients biopsies, imaging tests and even unnecessary surgeries."
The test was described in detail in a paper published in the June 28, 2016, online edition of the journal Nature Communications.
Related Links:
Ontario Institute for Cancer Research
University Health Network
Eastern Virginia Medical School
Investigators at the Ontario Institute for Cancer Research (Toronto, Canada) and their colleagues at the University Health Network (Toronto, Canada) and the Eastern Virginia Medical School (Norfolk, VA, USA) used advanced proteomics techniques to generate expression information for 624 proteins obtained in urine samples. Computational analyses reduced this number by identifying significantly differentially expressed proteins and finally characterized a set of six protein biomarkers for diagnosis and a set of seven protein biomarkers for prognosis of prostate cancer.
"The amazing thing about these signatures is that their rate of accuracy is as good or better than the invasive tests that are used today, with far fewer drawbacks," said contributing author Dr. Paul Boutros, a principal investigator at the Ontario Institute for Cancer Research. "They can replace invasive, expensive, uncomfortable tests with something much easier and simpler. This type of cheap, non-invasive testing could allow patients to be screened much more frequently, allowing for more accurate monitoring of patients' non-aggressive cancer over time, sparing patients biopsies, imaging tests and even unnecessary surgeries."
The test was described in detail in a paper published in the June 28, 2016, online edition of the journal Nature Communications.
Related Links:
Ontario Institute for Cancer Research
University Health Network
Eastern Virginia Medical School
Latest Pathology News
- Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
- AI Advancements Enable Leap into 3D Pathology
- New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy